Zevra Therapeutics (ZVRA) Accumulated Depreciation & Amortization (2018 - 2024)
Historic Accumulated Depreciation & Amortization for Zevra Therapeutics (ZVRA) over the last 9 years, with Q4 2024 value amounting to $1.7 million.
- Zevra Therapeutics' Accumulated Depreciation & Amortization rose 563.04% to $1.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.7 million, marking a year-over-year increase of 563.04%. This contributed to the annual value of $1.7 million for FY2024, which is 563.04% up from last year.
- Per Zevra Therapeutics' latest filing, its Accumulated Depreciation & Amortization stood at $1.7 million for Q4 2024, which was up 563.04% from $1.6 million recorded in Q4 2023.
- In the past 5 years, Zevra Therapeutics' Accumulated Depreciation & Amortization ranged from a high of $1.9 million in Q4 2021 and a low of $1.4 million during Q4 2022
- Over the past 5 years, Zevra Therapeutics' median Accumulated Depreciation & Amortization value was $1.7 million (recorded in 2020), while the average stood at $1.7 million.
- In the last 5 years, Zevra Therapeutics' Accumulated Depreciation & Amortization plummeted by 2503.9% in 2022 and then soared by 1323.63% in 2023.
- Over the past 5 years, Zevra Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $1.7 million in 2020, then rose by 11.53% to $1.9 million in 2021, then dropped by 25.04% to $1.4 million in 2022, then grew by 13.24% to $1.6 million in 2023, then increased by 5.63% to $1.7 million in 2024.
- Its Accumulated Depreciation & Amortization was $1.7 million in Q4 2024, compared to $1.6 million in Q4 2023 and $1.4 million in Q4 2022.